|
Sutro Biopharma is a private biopharmaceutical company headquartered in South San Francisco that develops antibody-drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. The current CEO, William Newell, joined Sutro in January 2009. Newell has over 15 years of senior management experience in the biotechnology industry, and has worked for companies such as Aerovance, QLT, Inc., and Ayxs Pharmaceuticals, Inc. Sutro’s CFO, Edward Albini, previously worked at Itero Biopharmaceuticals, Novacea, and Lynx Therapeutics. The CSO, Trevor Hallam, formerly worked at Palatin Technologies, AstraZeneca, Glaxo Group Research, and Roche Research Centre. The company received $26M in Series D funding in December 2013. The company’s investors include Alta Partners, Skyline Ventures, SV Life Sciences, Lilly Ventures, Amgen Ventures and Celgene. ==Technology== Sutro's Xpress CF and Xpress CF+ technologies are based on Stanford Professor James R. Swartz's patented Open Cell-Free Synthesis (OCFS) technology. The platform allows the parallel expression of hundreds of protein variants, including those incorporating non-natural amino acids, in as little as two weeks. Sutro’s cell-free expression technology provides a platform for the discovery and development of antibody-drug conjugates (ADCs). Once identified, production of protein drug candidates can be scaled in Sutro’s cGMP manufacturing facility located in San Carlos, CA. Importantly, Xpress CF was nominated for best scientific innovation by World ADC in 2014 and Sutro Biopharma was named one of FierceBiotech’s Fierce 15 in 2014. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Sutro Biopharma」の詳細全文を読む スポンサード リンク
|